Skip to main content
SpringerLink
Log in

Desmoid Tumors

  • Chapter
  • First Online:
Radiation Therapy for Sarcomas and Skin Cancers

Part of the book series: Practical Guides in Radiation Oncology ((PGRO))

  • 341 Accesses

Abstract

Desmoid tumors are benign soft tissue tumors with an unpredictable natural history. Some desmoid tumors may behave in and indolent fashion or spontaneously regress, while others may behave in a locally aggressive fashion causing significant morbidity or even mortality. Observation, surgery, systemic therapy, and radiation therapy (RT) may all play a role in the optimal management of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Reitamo JJ, Hayry P, Nykyri E, Saxen E. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77(6):665–73. https://doi.org/10.1093/ajcp/77.6.665.

    Article  Google Scholar 

  2. Lazar AJF, Tuvin D, Hajibashi S, et al. Specific mutations in the β-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173(5):1518–27. https://doi.org/10.2353/ajpath.2008.080475.

    Article  Google Scholar 

  3. Aitken SJ, Presneau N, Kalimuthu S, et al. Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses. Virchows Arch. 2015;467(2):203–10. https://doi.org/10.1007/s00428-015-1765-0.

    Article  Google Scholar 

  4. Nieuwenhuis MH, Lefevre JH, Bülow S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum. 2011;54(10):1229–34. https://doi.org/10.1097/DCR.0b013e318227e4e8.

    Article  Google Scholar 

  5. Bertario L, Russo A, Sala P, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer. 2001;95(2):102–7. https://doi.org/10.1002/1097-0215(20010320)95:2<102::AID-IJC1018>3.0.CO;2-8.

    Article  Google Scholar 

  6. Gansar GF, Markowitz IP, Cerise EJ. Thirty years of experience with desmoid tumors at Charity Hospital. Am Surg. 1987;53(6):318–9. http://www.ncbi.nlm.nih.gov/pubmed/3579044. Accessed 13 Sep 2019.

    Google Scholar 

  7. De Cian F, Delay E, Rudigoz RC, Ranchère D, Rivoire M. Desmoid tumor arising in a cesarean section scar during pregnancy: monitoring and management. Gynecol Oncol. 1999;75(1):145–8. https://doi.org/10.1006/gyno.1999.5539.

    Article  Google Scholar 

  8. Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its β-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am J Pathol. 1998;153(3):709–14. https://doi.org/10.1016/S0002-9440(10)65614-3.

    Article  Google Scholar 

  9. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997;151(2):329–34. http://www.ncbi.nlm.nih.gov/pubmed/9250146. Accessed 13 Sep 2019.

    Google Scholar 

  10. Ungerbäck J, Elander N, Grünberg J, Sigvardsson M, Söderkvist P. The Notch-2 gene is regulated by Wnt signaling in cultured colorectal cancer cells. PLoS One. 2011;6(3):e17957. https://doi.org/10.1371/journal.pone.0017957.

    Article  Google Scholar 

  11. Kim H-A, Koo B-K, Cho J-H, et al. Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer. J Clin Invest. 2012;122(9):3248–59. https://doi.org/10.1172/JCI61216.

    Article  Google Scholar 

  12. Shang H, Braggio D, Lee Y-J, et al. Targeting the notch pathway: a potential therapeutic approach for desmoid tumors. Cancer. 2015;121(22):4088–96. https://doi.org/10.1002/cncr.29564.

    Article  Google Scholar 

  13. Timbergen MJM, Smits R, Grünhagen DJ, Verhoef C, Sleijfer S, Wiemer EAC. Activated signaling pathways and targeted therapies in desmoid-type fibromatosis: a literature review. Front. Oncologia. 2019;9 https://doi.org/10.3389/fonc.2019.00397.

  14. Salas S, Chibon F, Noguchi T, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosom Cancer. 2010;49(6):560–8. https://doi.org/10.1002/gcc.20766.

    Article  Google Scholar 

  15. Kurtz JE, Buy X, Sauleau EA, Toulmonde M, Deschamps F, Honoré C, Bouhamama A, Blay JYGA. CRYODESMO-O1: a French nationwide phase II study on cryoablation in progressing desmoid tumour (DT) patients (pts). Ann Oncol. 2019;30(Suppl 5):v683.

    Article  Google Scholar 

  16. Trautmann M, Rehkämper J, Gevensleben H, et al. Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis—a systematic analysis of 204 cases. Sci Rep. 2020;10(1):3368. https://doi.org/10.1038/s41598-020-60237-6.

    Article  Google Scholar 

  17. Bonvalot S, Ternes N, Fiore M, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20(13):4096–102. https://doi.org/10.1245/s10434-013-3197-x.

    Article  Google Scholar 

  18. Burtenshaw SM, Cannell AJ, McAlister ED, et al. Toward observation as first-line management in abdominal desmoid tumors. Ann Surg Oncol. 2016;23(7):2212–9. https://doi.org/10.1245/s10434-016-5159-6.

    Article  Google Scholar 

  19. de Bruyns A, Li H, MacNeil A, et al. Evolving practice patterns over two decades (1993–2013) in the management of desmoid-type fibromatosis in British Columbia. Clin Oncol. 2019; https://doi.org/10.1016/j.clon.2019.10.005.

  20. Turner B, Alghamdi M, Henning JW, et al. Surgical excision versus observation as initial management of desmoid tumors: a population based study. Eur J Surg Oncol. 2019;45(4):699–703. https://doi.org/10.1016/j.ejso.2018.09.015.

    Article  Google Scholar 

  21. Suit H, Spiro I. Radiation treatment of benign mesenchymal disease. Semin Radiat Oncol. 1999;9(2):171–8. https://doi.org/10.1016/S1053-4296(99)80007-1.

    Article  Google Scholar 

  22. Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998;40(3):637–45. https://doi.org/10.1016/S0360-3016(97)00845-6.

    Article  Google Scholar 

  23. Ballo MT, Zagars GK, Pollack A, Pisters PWT, Pollock RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17(1):158–67. https://doi.org/10.1200/jco.1999.17.1.158.

    Article  Google Scholar 

  24. Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol. 2011;29(26):3553–8. https://doi.org/10.1200/JCO.2010.33.5489.

    Article  Google Scholar 

  25. Harati K, Jaenisch A, Behr B, et al. Effect of surgical margins on prognosis in aggressive fibromatosis: a single-institutional analysis of 90 patients. Oncol Lett. 2017;14(5):5129–34. https://doi.org/10.3892/ol.2017.6864.

    Article  Google Scholar 

  26. O’Dea FJ, Wunder J, Bell RS, Griffin AM, Catton C, O’Sullivan B. Preoperative radiotherapy is effective in the treatment of fibromatosis. In: Clinical orthopaedics and related research. Lippincott Williams and Wilkins; 2003:19–24. doi:https://doi.org/10.1097/01.blo.0000093892.12372.d4.

  27. Yao X, Corbett T, Gupta AA, et al. A systematic review of active treatment options in patients with Desmoid tumours. Curr Oncol. 2014;21(4):613–29. https://doi.org/10.3747/co.21.1995.

    Article  Google Scholar 

  28. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71(2):441–7. https://doi.org/10.1016/j.ijrobp.2007.10.013.

    Article  Google Scholar 

  29. Rüdiger HA, Ngan SYK, Ng M, Powell GJ, Choong PFM. Radiation therapy in the treatment of desmoid tumours reduces surgical indications. Eur J Surg Oncol. 2010;36(1):84–8. https://doi.org/10.1016/j.ejso.2009.07.183.

    Article  Google Scholar 

  30. Santti K, Beule A, Tuomikoski L, et al. Radiotherapy in desmoid tumors treatment response, local control, and analysis of local failures; 2017. https://doi.org/10.1007/s00066-016-1091-8.

    Book  Google Scholar 

  31. Janssen ML, van Broekhoven DLM, Cates JMM, et al. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg. 2017;104(4):347–57. https://doi.org/10.1002/bjs.10477.

    Article  Google Scholar 

  32. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol. 1998;42(5):1007–14. https://doi.org/10.1016/S0360-3016(98)00285-5.

    Article  Google Scholar 

  33. Goy BW, Lee SP, Eilber F, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol. 1997;39(3):659–65. https://doi.org/10.1016/S0360-3016(97)00334-9.

    Article  Google Scholar 

  34. Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001;92(5):1259–64. https://doi.org/10.1002/1097-0142(20010901)92:5<1259::AID-CNCR1446>3.0.CO;2-Y.

    Article  Google Scholar 

  35. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer. 1993;72(11):3244–7. https://doi.org/10.1002/1097-0142(19931201)72:11<3244::AID-CNCR2820721118>3.0.CO;2-D.

    Article  Google Scholar 

  36. Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol. 2006;24(1):102–5. https://doi.org/10.1200/JCO.2005.02.1923.

    Article  Google Scholar 

  37. Bocale D, Rotelli MT, Cavallini A, Altomare DF. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Color Dis. 2011;13(12):e388–95. https://doi.org/10.1111/j.1463-1318.2011.02758.x.

    Article  Google Scholar 

  38. Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol. 2003;14:181–90. https://doi.org/10.1093/annonc/mdg064.

    Article  Google Scholar 

  39. Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG) original articles Annals of Oncology. Ann Oncol. 2012;23:182–6. https://doi.org/10.1093/annonc/mdr051.

    Article  Google Scholar 

  40. Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter sarcoma Alliance for research through collaboration (SARC) trial. Clin Cancer Res. 2010;16(19):4884–91. https://doi.org/10.1158/1078-0432.CCR-10-1177.

    Article  Google Scholar 

  41. Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French sarcoma group phase II trial with a long-term follow-up. Ann Oncol. 2011;22:452–7. https://doi.org/10.1093/annonc/mdq341.

    Article  Google Scholar 

  42. Kasper B, Gruenwald V, Reichardt P, Bauer S, Hohenberger P, Haller F. Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with Imatinib: translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01). Ann Surg Oncol. 2016;23(6):1924–7. https://doi.org/10.1245/s10434-016-5132-4.

    Article  Google Scholar 

  43. Kasper B, Gruenwald V, Reichardt P, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017;76:60–7. https://doi.org/10.1016/j.ejca.2017.02.001.

    Article  Google Scholar 

  44. Gounder MM, Mahoney MR, Van Tine B, et al. Sorafenib for advanced and refractory desmoid tumors. NEJM. 2018;379:2417–28.

    Article  Google Scholar 

  45. Acker JC, Bossen EH, Halperin EC. The management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1993;26(5):851–8. https://doi.org/10.1016/0360-3016(93)90501-L.

    Article  Google Scholar 

  46. Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013;258(2):347–53. https://doi.org/10.1097/SLA.0b013e31828c8a30.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, MultiCare Regional Cancer Center, Tacoma General Hospital, Tacoma, WA, USA

    Chan-Kyung Jane Cho

  2. Department of Radiation Oncology, University of Washington, Seattle, WA, USA

    Edward Kim

Authors
  1. Chan-Kyung Jane Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Kim .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University of Washington, Seattle, WA, USA

    Edward Kim

  2. Department of Radiation Oncology, University of Washington, Seattle, WA, USA

    Upendra Parvathaneni

  3. Department of Radiation Oncology, The Ohio State University James Cancer Center, Columbus, OH, USA

    Meng Xu Welliver

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cho, CK.J., Kim, E. (2022). Desmoid Tumors. In: Kim, E., Parvathaneni, U., Welliver, M.X. (eds) Radiation Therapy for Sarcomas and Skin Cancers. Practical Guides in Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-031-06706-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-06706-8_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-06705-1

  • Online ISBN: 978-3-031-06706-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation